Antibody-based detection of lysine modification of hepatic protein in mice treated with retrorsine

References

• Stegelmeier BL, Edgar JA, Colegate SM, et al. Pyrrolizidine alkaloid plants, metabolism and toxicity. J Nat Toxins. 1999;8(1):95–116.
   PubMedGoogle Scholar
• Edgar JA, Molyneux RJ, Colegate SM. Pyrrolizidine alkaloids: potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol. 2015;28(1):4–20. doi:10.1021/tx500403t.
   PubMed Web of Science ®Google Scholar
• Mattocks AR. Chemistry and Toxicology of Pyrrolizidine Alkaloids. London: Academic Press; 1986.
   Google Scholar
• Roeder E. Medicinal plants in China containing pyrrolizidine alkaloids. Pharmazie. 2000;55(10):711–726.
   PubMed Web of Science ®Google Scholar
• Roeder E. Medicinal plants in Europe containing pyrrolizidine alkaloids. Pharmazie. 1995;50(2):83–98.
   PubMed Web of Science ®Google Scholar
• Smith LW, Culvenor CC. Plant sources of hepatotoxic pyrrolizidine alkaloids. J Nat Prod. 1981;44(2):129–152. doi:10.1021/np50014a001.
   PubMed Web of Science ®Google Scholar
• Li N, Xia Q, Ruan J, et al. Hepatotoxicity and tumorigenicity induced by metabolic activation of pyrrolizidine alkaloids in herbs. Curr Drug Metab. 2011;12(9):823–834. doi:10.2174/138920011797470119.
   PubMed Web of Science ®Google Scholar
• Fu PP, Xia Q, Ming WC, et al. Detection, hepatotoxicity, and tumorigenicity of pyrrolizidine alkaloids in Chinese herbal plants and herbal dietary supplements. J Food Drug Anal. 2007; 15:400–415.
   Web of Science ®Google Scholar
• Chojkier M. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol. 2003;39(3):437–446. doi:10.1016/S0168-8278(03)00231-9.
   PubMed Web of Science ®Google Scholar
• Chen Z, Huo JR. Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations. Neth J Med. 2010;68(6):252–260.
   PubMed Web of Science ®Google Scholar
• Ruan JQ, Liao C, Ye Y, et al. Lack of metabolic activation and predominant formation of an excreted metabolite of nontoxic platynecine-type pyrrolizidine alkaloids. Chem Res Toxicol. 2014;27(1):7–16. doi:10.1021/tx4004159.
   PubMed Web of Science ®Google Scholar
• Ruan JQ, Yang MB, Fu PP, et al. Metabolic activation of pyrrolizidine alkaloids: insights into the structural and enzymatic basis. Chem Res Toxicol. 2014;27(6):1030–1039. doi:10.1021/tx500071q.
   PubMed Web of Science ®Google Scholar
• Fu PP, Xia Q, Lin G, et al. Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev. 2004;36(1):1–55. doi:10.1081/dmr-120028426.
   PubMed Web of Science ®Google Scholar
• Willmot FC, Robertson GW. Senecio disease or cirrhosis of the liver due to Senecio poisoning. Lancet. 1920;196(5069):848–849. doi:10.1016/S0140-6736(01)00020-4.
   Google Scholar
• Dai N, Yu YC, Ren TH, et al. Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature. World J Gastroenterol. 2007;13(10):1628–1631. doi:10.3748/wjg.v13.i10.1628.
   PubMed Web of Science ®Google Scholar
• Fu PP, Xia Q, He X, et al. Detection of pyrrolizidine alkaloid DNA Adducts in livers of cattle poisoned with Heliotropium europaeum. Chem Res Toxicol. 2017;30(3):851–858. doi:10.1021/acs.chemrestox.6b00456.
   PubMed Web of Science ®Google Scholar
• Yang X, Li W, Sun Y, et al. Comparative study of hepatotoxicity of pyrrolizidine alkaloids retrorsine and monocrotaline. Chem Res Toxicol. 2017;30(2):532–539. doi:10.1021/acs.chemrestox.6b00260.
   PubMed Web of Science ®Google Scholar
• Mingatto FE, Dorta DJ, dos Santos AB, et al. Dehydromonocrotaline inhibits mitochondrial complex I. A potential mechanism accounting for hepatotoxicity of monocrotaline. Toxicon. 2007;50(5):724–730. doi:10.1016/j.toxicon.2007.06.006.
   Web of Science ®Google Scholar
• Jiang Y, Fu PP, Lin G. Hepatotoxicity of naturally occuring pyrrolizidine alkaloids. Asian J Pharmacokinet Pharmacodyn. 2006; 6:187–192.
   Google Scholar
• Mattocks AR, Driver HE, Barbour RH, et al. Metabolism and toxicity of synthetic analogues of macrocyclic diester pyrrolizidine alkaloids. Chem Biol Interact. 1986;58(1):95–108. doi:10.1016/S0009-2797(86)80089-8.
   Web of Science ®Google Scholar
• Lin G, Cui YY, Hawes EM. Microsomal formation of a pyrrolic alcohol glutathione conjugate of clivorine. Firm evidence for the formation of a pyrrolic metabolite of an otonecine-type pyrrolizidine alkaloid. Drug Metab Dispos. 1998;26(2):181–184.
   Web of Science ®Google Scholar
• Lin G, Cui YY, Hawes EM. Characterization of rat liver microsomal metabolites of clivorine, an hepatotoxic otonecine-type pyrrolizidine alkaloid. Drug Metab Dispos. 2000;28(12):1475–1483.
   Web of Science ®Google Scholar
• Lin G, Wang JY, Li N, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol. 2011;54(4):666–673. doi:10.1016/j.jhep.2010.07.031.
   PubMed Web of Science ®Google Scholar
• Fashe MM, Juvonen RO, Petsalo A, et al. In silico prediction of the site of oxidation by cytochrome P450 3A4 that leads to the formation of the toxic metabolites of pyrrolizidine alkaloids. Chem Res Toxicol. 2015;28(4):702–710. doi:10.1021/tx500478q.
   Web of Science ®Google Scholar
• Yan CC, Huxtable RJ. Relationship between glutathione concentration and metabolism of the pyrrolizidine alkaloid, monocrotaline, in the isolated, perfused liver. Toxicol Appl Pharmacol. 1995;130(1):132–139. doi:10.1006/taap.1995.1017.
   Web of Science ®Google Scholar
• Li N, Zhang F, Lian W, et al. Immunoassay approach for diagnosis of exposure to pyrrolizidine alkaloids. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2017; 16:1–13.
   Google Scholar
• Mattocks AR, White INH. Estimation of metabolites of pyrrolizidine alkaloids in animal tissues. Anal Biochem. 1970;38(2):529–535. doi:10.1016/0003-2697(70)90478-1.
   Web of Science ®Google Scholar
• Ruan J, Gao H, Li N, et al. Blood pyrrole-protein adducts-A biomarker of pyrrolizidine alkaloid-induced liver injury in humans . J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015;33(4):404–421. doi:10.1080/10590501.2015.1096882.
   Web of Science ®Google Scholar
• Li W, Wang K, Lin G, et al. Lysine adduction by reactive metabolite(s) of monocrotaline. Chem Res Toxicol. 2016;29(3):333–341. doi:10.1021/acs.chemrestox.5b00488.
   Web of Science ®Google Scholar
• Pumford NR, Roberts DW, Benson RW, et al. Immunochemical quantitation of 3-(cystein-S-yl) acetaminophen protein adducts in subcellular liver fractions following a hepatotoxic dose of acetaminophen. Biochem Pharmacol. 1990; 40(3):573–579. doi:10.1016/0006-2952(90)90558-3.
   PubMed Web of Science ®Google Scholar
• Martin JL, Meinwald J, Radford P, et al. Stereoselective metabolism of halothane enantiomers to trifluoroacetylated liver proteins. Drug Metab Rev. 1995; 27(1–2):179–189. doi:10.3109/03602539509029822.
   PubMed Web of Science ®Google Scholar
• Rombach EM, Hanzlik RP. Detection of adducts of bromobenzene 3,4-oxide with rat liver microsomal protein sulfhydryl groups using specific antibodies. Chem Res Toxicol. 1999; 12(2):159–163. doi:10.1021/tx980177v.
   Web of Science ®Google Scholar
• Zheng J, Hammock BD. Development of polyclonal antibodies for detection of protein modification by 1,2-naphthoquinone. Chem Res Toxicol. 1996; 9(5):904–909. doi:10.1021/tx960014b.
   Web of Science ®Google Scholar
• Halmes NC, McMillan DC, Oatis JE, Jr, et al. Immunochemical detection of protein adducts in mice treated with trichloroethylene. Chem Res Toxicol. 1996;9(2):451–456. doi:10.1021/tx950171v.
   Web of Science ®Google Scholar
• Shen S, Zhang F, Zeng S, et al. Development of enantioselective polyclonal antibodies to detect styrene oxide protein adducts. Anal Chem. 2009; 81(7):2668–2677. doi:10.1021/ac8023262.
   Web of Science ®Google Scholar
• Chen M, Li L, Zhong D, et al. 9-Glutathionyl-6,7-dihydro-1-hydroxymethyl-5H-pyrrolizine is the major pyrrolic glutathione conjugate of retronecine-type pyrrolizidine alkaloids in liver microsomes and in rats. Chem Res Toxicol. 2016; 29(2):180–189. doi:10.1021/acs.chemrestox.5b00427.
   PubMedGoogle Scholar